|
1.
|
|
12 p, 945.0 KB |
Participatory action research intervention for improving sleep in inpatients with cancer
/
Cabrera Jaime, Sandra (Institut d'Investigació Biomèdica de Bellvitge) ;
Martinez, Cristina (Institut d'Investigació Biomèdica de Bellvitge) ;
Gonzalo Bachiller, Verónica (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Zarza Arnau, Nuria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martin Maldonado, Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Belén Manrique Palles, Ana (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Artiga Sarrion, Inmaculada (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Tierno Sanchez, Noelia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Julià Torras, Joaquim (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sancho, Juan Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Cabrera Jaime, Laura (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Aim: To design and implement a plan to improve oncohaematological patients' sleep. Background: The hospital environment can compromise inpatients' sleep, negatively impacting on health outcomes and patient satisfaction. [...]
2023 -  10.1111/jocn.16279
Journal of clinical nursing, Vol. 32 Núm. 7-8 (april 2023) , p. 1218-1229
|
|
|
2.
|
|
10 p, 3.3 MB |
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia : results of the BURKIMAB14 trial
/
Ribera, Josep Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Morgades, Mireia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Garcia-Calduch, Olga (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sirvent, Maialen (Hospital Universitario de Donostia) ;
Buendia, Buenaventura (Hospital Universitario 12 de Octubre) ;
Cervera, Marta (Institut Catala d'Oncologia-Hospital Joan XXIII) ;
Luzardo, Hugo (Hospital Universitario de Gran Canaria Dr. Negrin) ;
Hernandez-Rivas, Jesus Maria (Hospital Universitario de Salamanca) ;
Sitges, Marta (Hospital Universitari de Girona Doctor Josep Trueta) ;
Garcia-Cadenas, Irene (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Abrisqueta, Pau (Hospital Universitari Vall d'Hebron) ;
Montesinos, Pau (Hospital Universitari i Politècnic La Fe (València)) ;
Bastos-Oreiro, Mariana (Hospital General Universitario Gregorio Marañón) ;
De Llano, Maria Paz Queipo (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Bravo, Pilar (Hospital Universitario de Fuenlabrada. Madrid) ;
Torrent, Anna (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Herrera, Pilar (Hospital Universitario Ramon y Cajal) ;
Garcia-Guinon, Antonni (Hospital Universitari Arnau de Vilanova) ;
Vall-Llovera, Ferran (Hospital Universitari MútuaTerrassa) ;
Serrano, Josefina (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ;
Terol, Maria José (Hospital Clinico Universitario de Valencia) ;
Bergua, Juan Miguel (Hospital San Pedro de Alcántara) ;
Garcia-Noblejas, Ana (Hospital Universitario de La Princesa) ;
Barrenetxea, Cristina (Hospital Universitario Basurto) ;
Llorente, Laura (Hospital Universitario HM Sanchinarro (Madrid)) ;
Garcia-Belmonte, Daniel (Hospital Universitario La Zarzuela) ;
Gimeno, Eva (Hospital del Mar (Barcelona, Catalunya)) ;
Cladera, Antonia (Hospital Universitari Son Llatzer) ;
Mercadal, Santiago (Institut Català d'Oncologia) ;
Sancho, Juan Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
High dose-intensive or infusional intermediate-dose immunochemotherapy is highly effective treatment for Burkitt lymphoma irrespective of human immunodeficiency virus (HIV) infection. However, toxicities of these regimens are relevant, especially in older adults and elderly patients. [...]
2024 - 10.3324/haematol.2023.283342
Haematologica, Vol. 109 Núm. 2 (january 2024) , p. 543-552
|
|
|
3.
|
|
9 p, 821.4 KB |
Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma : Final Results of a Randomized Phase III Study
/
Kwak, Larry W. (Comprehensive Cancer Center, Duarte) ;
Sancho, Juan Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Cho, Seok Goo (The Catholic University of Korea, Seoul, South Korea) ;
Nakazawa, Hideyuki (Shinshu University School of Medicine, Nagano, Japan) ;
Suzumiya, Junji (Shimane University Hospital, Innovative Cancer Center/Oncology-Hematology, Izumo, Japan) ;
Tumyan, Gayane (Division of Hematology and Bone Marrow Transplantation, Blokhin Russian Cancer) ;
Kim, Jin Seok (Yonsei University College of Medicine, Severance Hospital, Seoul, South Korea) ;
Menne, Tobias (Newcastle University, UK) ;
Mariz, José (Instituto Português de Oncología do Porto) ;
Ilyin, Nikolai (Ministry of Health of the Russian Federation) ;
Jurczak, Wojciech (Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland) ;
Lopez Martinez, Aurelio (Hospital Arnau de Vilanova (València)) ;
Samoilova, Olga (Nizhniy Novgorod Region Clinical Hospital, Nizhniy Novgorod, Russia) ;
Zhavrid, Edvard (N. N. Alexandrov Republican Scientific and Practical Centre of Oncology and Medical Radiology, Belarus) ;
Yañez Ruiz, Eduardo (Universidad de la Frontera, Temuco, Chile) ;
Trneny, Marek (Charles University, Czech Republic) ;
Popplewell, Leslie (Toni Stephenson Lymphoma Cancer Center and Department of Hematology and Hematopoietic Cell Transplantation, Duarte, CA) ;
Ogura, Michinori (Kasugai Municipal Hospital, Aichi 486-8510, Japan.) ;
Kim, Wong Seog (Sungkyunkwan University School of Medicine, Seoul, South Korea) ;
Lee, Sang Joon (Celltrion. Inc, South Korea) ;
Kim, Sung Hyun (Celltrion. Inc, South Korea) ;
Ahn, Keum Young (Celltrion. Inc, South Korea) ;
Buske, Christian (University Hospital of Ulm, Germany)
Introduction: This double-blind, parallel-group, active-controlled phase III trial (NCT02260804) assessed CT-P10 and rituximab safety and efficacy in patients with previously untreated low-tumor-burden follicular lymphoma (LTBFL), including after a single switch from rituximab to CT-P10. [...]
2022 - 10.1016/j.clml.2021.08.005
Clinical Lymphoma, Myeloma & Leukemia, Vol. 22 Núm. 2 (february 2022) , p. 89-97
|
|
|
4.
|
|
10 p, 2.0 MB |
Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets
/
Karube, K. (University of the Ryukyus) ;
Enjuanes, A. (Hospital Clínic i Provincial de Barcelona) ;
Dlouhy, I. (Hospital Clínic i Provincial de Barcelona) ;
Jares, Pedro (Hospital Clínic i Provincial de Barcelona) ;
Martín-García, David (Hospital Clínic i Provincial de Barcelona) ;
Nadeu, Ferran (Hospital Clínic i Provincial de Barcelona) ;
Ordóñez, G.R. (DREAMgenics) ;
Rovira, Jordi (Hospital Clínic i Provincial de Barcelona) ;
Clot, Guillem (Hospital Clínic i Provincial de Barcelona) ;
Royo, C. (Hospital Clínic i Provincial de Barcelona) ;
Navarro, A. (Hospital Clínic i Provincial de Barcelona) ;
Gonzalez-Farre, B. (Hospital Clínic i Provincial de Barcelona) ;
Vaghefi, A. (Hospital Clínic i Provincial de Barcelona) ;
Castellano, G. (Hospital Clínic i Provincial de Barcelona) ;
Rubio-Perez, C. (Universitat Pompeu Fabra) ;
Tamborero, D. (Universitat Pompeu Fabra) ;
Briones Meijide, Javier (Institut d'Investigació Biomèdica Sant Pau) ;
Salar, A. (Hospital del Mar (Barcelona, Catalunya)) ;
Sancho, J.M. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Mercadal, S. (ICO-Hospital Duran i Reynals) ;
Gonzalez-Barca, E. (ICO-Hospital Duran i Reynals) ;
Escoda, L. (Hospital Universitari Joan XXIII de Tarragona) ;
Miyoshi, H. (Kurume University School of Medicine) ;
Ohshima, K. (Kyushu University) ;
Miyawaki, K. (Kyushu University) ;
Kato, K. (Kyushu University) ;
Akashi, K. (Kyushu University) ;
Mozos, Ana (Institut d'Investigació Biomèdica Sant Pau) ;
Colomo, L. (Hospital del Mar (Barcelona, Catalunya)) ;
Alcoceba, Miguel (Hospital Universitario de Salamanca) ;
Valera, A. (Hospital Clínic i Provincial de Barcelona) ;
Carrió, A. (Hospital Clínic i Provincial de Barcelona) ;
Costa, D. (Institució Catalana de Recerca i Estudis Avançats) ;
Lopez-Bigas, N. (National Institutes of Health (Bethesda, Estats Units d'Amèrica)) ;
Schmitz, R. (National Institutes of Health (Bethesda, Estats Units d'Amèrica)) ;
Staudt, L.M. (Hospital Clínic i Provincial de Barcelona) ;
Salaverria, I. (Hospital Clínic i Provincial de Barcelona) ;
López-Guillermo, A. (Hospital Clínic i Provincial de Barcelona) ;
Campo, E. (Hospital Clínic i Provincial de Barcelona) ;
Universitat Autònoma de Barcelona
Genome studies of diffuse large B-cell lymphoma (DLBCL) have revealed a large number of somatic mutations and structural alterations. However, the clinical significance of these alterations is still not well defined. [...]
2018 - 10.1038/leu.2017.251
Leukemia, Vol. 32 Núm. 3 (january 2018) , p. 675-684
|
|
|
5.
|
|
6 p, 2.8 MB |
HHV8 and EBV-negative primary effusion-based lymphoma : A case report of a new provisional entity and review of literature
/
Canelo-Vilaseca, Marta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Tapia, Gustavo (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Orna, Elisa (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sorigue, Marc (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Granada, Isabel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Palomar-Muñoz, Azahara (Hospital Universitari de Bellvitge) ;
Castillo, Ana (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Grau Cat, Javier (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Mesa Tudel, Alba (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sancho, Juan-Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Navarro, José-Tomás (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
HHV8- and EBV-negative primary effusion lymphoma is an extremely rare neoplasm involving body cavities without detectable tumor mass. It usually presents in elderly patients without known immunodeficiency. [...]
2023 - 10.1002/ccr3.7282
Clinical Case Reports, Vol. 11 (may 2023)
|
|
|
6.
|
|
12 p, 927.8 KB |
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
/
Kwon, Mi (Hospital General Universitario Gregorio Marañón) ;
Iacoboni, Gloria (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Reguera-Ortega, Juan Luis (Instituto de Biomedicina de Sevilla) ;
Corral, Lucía López (Instituto de Investigación Biomédica de Salamanca) ;
Morales, Rafael Hernani (Hospital Clínic Universitari (València)) ;
Ortiz-Maldonado, Valentín (Hospital Clínic i Provincial de Barcelona) ;
Guerreiro, Manuel (Hospital Universitari i Politècnic La Fe (València)) ;
Caballero, Ana Carolina (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Domínguez, María Luisa Guerra (Hospital Universitario de Gran Canaria Dr. Negrín) ;
Pina, Jose Maria Sanchez (Hospital Universitario 12 de Octubre (Madrid)) ;
Mussetti, Alberto (Institut Català d'Oncologia) ;
Sancho, Juan-Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bastos, Mariana (Hospital General Universitario Gregorio Marañón) ;
Catala, Eva (Vall d'Hebron Institut d'Oncologia) ;
Delgado, Javier (Instituto de Biomedicina de Sevilla) ;
Henriquez, Hugo Luzardo (Hospital Universitario de Gran Canaria Dr. Negrín) ;
Sanz, Jaime (Hospital Universitari i Politècnic La Fe (València)) ;
Calbacho, Maria (Hospital Universitario 12 de Octubre (Madrid)) ;
Bailén, Rebeca (Hospital General Universitario Gregorio Marañón) ;
Carpio Segura, Cecilia del Carmen (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Ribera Santasusana, Jose Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sureda, Anna (Institut Català d'Oncologia) ;
Briones Meijide, Javier (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Hernandez-Boluda, Juan Carlos (Hospital Clínic Universitari (València)) ;
Cebrián, Nuria Martínez (Hospital Clínic i Provincial de Barcelona) ;
Martin, Jose Luis Diez (Universidad Complutense de Madrid) ;
Martín, Alejandro (Instituto de Investigación Biomédica de Salamanca) ;
Barba, Pere (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We performed a retrospective study to evaluate safety and efficacy of axi-cel and tisa-cel outside the setting of a clinical trial. [...]
2022 - 10.3324/haematol.2022.280805
Haematologica, Vol. 108 (january 2023) , p. 110-121
|
|
|
7.
|
|
13 p, 520.5 KB |
R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years : Results of a randomized phase 2 study from the Spanish GELTAMO group
/
Sancho, Juan-Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fernández-Alvarez, Rubén (Hematology Department. Hospital de Cabueñes) ;
Gual-Capllonch, Francisco (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
González García, Esther (Hematology Department. Hospital de Cabueñes) ;
Grande García, Carlos (Hospital Universitario 12 de Octubre (Madrid)) ;
Gutierrez, Norma (Instituto de Investigación Biomédica de Salamanca) ;
Peñarrubia, María Jesús (Hospital Clínico Universitario de Valladolid) ;
Batlle-López, Ana (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
González Barca, Eva (Hospital Duran i Reynals (Hospitalet del Llobregat)) ;
Guinea de Castro, José María (Arabako Unibertsitate Ospitalea (Vitoria, País Basc)) ;
Gimeno, Eva (Hospital del Mar (Barcelona, Catalunya)) ;
Peñalver Parraga, Francisco Javier (Hematology Department. Hospital Universitario Fundación de Alcorcón) ;
Fuertes, Miguel Ángel (Hospital Clínico Universitario Lozano Blesa (Zaragoza)) ;
Bastos, Mariana (Hospital General Universitario Gregorio Marañón) ;
Hernandez-Rivas, JA (Hospital Universitario Infanta Leonor) ;
Moraleda, José María (Hospital Universitario Virgen de la Arrixaca (Múrcia)) ;
García, Olga (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sorigue, Marc (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Martín García-Sancho, Alejandro (Instituto de Investigación Biomédica de Salamanca)
The use of non-pegylated liposomal doxorubicin (Myocet) in diffuse large B-cell lymphoma (DLBCL) has been investigated in retrospective and single-arm prospective studies. This was a prospective phase 2 trial of DLBCL patients ≥60 years old with left ventricular ejection fraction (LVEF) ≥55% randomized to standard R-CHOP or investigational R-COMP (with Myocet instead of conventional doxorubicin). [...]
2021 - 10.1002/cam4.3730
Cancer Medicine, Vol. 10 Núm. 4 (february 2021) , p. 1314-1326
|
|
|
8.
|
|
13 p, 463.3 KB |
Targeting CD19 in diffuse large B-cell lymphoma : An expert opinion paper
/
Bailly, Sarah (Département d'Hématologie. Cliniques Universitaires Saint-Luc) ;
Cartron, Guillaume (Centre Hospitalier Universitaire de Montpellier) ;
Chaganti, Sridhar ;
Cordoba, Raul (Hospital Universitario Fundación Jiménez Díaz) ;
Corradini, Paolo (University of Milan) ;
Düll, Johannes (Medizinische Klinik und Poliklinik II. Universitätsklinikum Würzburg) ;
Ferrarini, Isacco (Department of Medicine. Section of Hematology. University of Verona) ;
Osborne, Wendy (Newcastle Upon Tyne Hospitals NHS Foundation Trust) ;
Rosenwald, Andreas (University of Würzburg) ;
Sancho, Juan-Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Tilly, Hervé (Centre Henri Becquerel and University of Rouen) ;
Van Den Neste, Eric (Cliniques Universitaires Saint-Luc) ;
Viardot, Aandreas (University Hospital of Ulm (Alemanya)) ;
Visco, Carlo (University of Verona) ;
Universitat Autònoma de Barcelona
The ubiquitous, early-stage expression, efficient internalization, limited off-target effects, and high disease specificity of CD19 make it an attractive therapeutic target. Currently available anti-CD19 therapies have demonstrated particular promise in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. [...]
2022 - 10.1002/hon.3013
Hematological Oncology, Vol. 40 Núm. 4 (october 2022) , p. 505-517
|
|
|
9.
|
|
9 p, 575.4 KB |
Mortality among patients with low-grade follicular lymphoma : A binational retrospective analysis
/
Rajamäki, Aino (University of Eastern Finland) ;
Hujo, Mika (University of Eastern Finland) ;
Sund, Reijo (University of Eastern Finland) ;
Prusila, Roosa E. I. (University of Oulu) ;
Kuusisto, Milla E. L. (Oulu University Hospital (Finlàndia)) ;
Kuitunen, Hanne (Oulu University Hospital (Finlàndia)) ;
Jantunen, Esa (North Carelia Central Hospital) ;
Mercadal, Santiago (Hospital Duran i Reynals (Hospitalet del Llobregat)) ;
Sorigue, Marc (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sancho, Juan-Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sunela, Kaisa (Tampere University Hospital) ;
Kuittinen, Outi (Kuopio University Hospital ( Finlàndia)) ;
Universitat Autònoma de Barcelona
Background: The life expectancy of patients with follicular lymphoma (FL) has improved considerably since the introduction of rituximab. This study examined the proportion of deaths from progressive lymphoma and the impact of FL on survival compared with that in the general population. [...]
2022 - 10.1002/cncr.34221
Cancer, Vol. 128 Núm. 13 (january 2022) , p. 2474-2482
|
|
|
10.
|
|
5 p, 801.1 KB |
Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity
/
Fernandez-Rodríguez, Concepción (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Rodriguez-Sevilla, Juan Jose (Hospital del Mar (Barcelona, Catalunya)) ;
Fernández Ibarrondo, Lierni (Universitat Pompeu Fabra) ;
Sánchez-González, Blanca (Hospital del Mar (Barcelona, Catalunya)) ;
Gibert, Joan (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Bento, Leyre (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Garcia, Juan Fernando (MD Anderson Cancer Center) ;
Sancho, Juan-Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Díez-Feijoo, Ramón (Hospital del Mar (Barcelona, Catalunya)) ;
Camacho, Laura (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Garcia-Retortillo, M (Hospital del Mar (Barcelona, Catalunya)) ;
Gimeno, Eva (Hospital del Mar (Barcelona, Catalunya)) ;
Colomo, Luis (Universitat Pompeu Fabra) ;
Gutiérrez, Antonio (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Bellosillo Paricio, Beatriz (Universitat Pompeu Fabra) ;
Salar, Antonio (Hospital del Mar (Barcelona, Catalunya))
Epidemiological studies have demonstrated the association between hepatitis B virus (HBV) infection and B-cell non-Hodgkin lymphoma (NHL), mainly for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). [...]
2022 - 10.1182/bloodadvances.2021005316
Blood advances, Vol. 6 Núm. 1 (november 2022) , p. 82-86
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
